Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06491914 · ClinicalTrials.gov registry record · Phase 3
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
A Phase 3 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 1,118
- Enrollment target
- 20
- Study locations
NCT06491914: Active Phase 3 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, sponsored by Regeneron Pharmaceuticals.
NCT06491914 is a Phase 3 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 1,118 participants, below the 3,777-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06491914, a Phase 3 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,118 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on participants with nAMD and DME that have been previously treated with anti-vascular endothelial growth factor (anti-VEGF) medications. The aim of the study is to see how safe and effective aflibercept HD injections are when given as frequently as every 4 weeks. The study is also looking at what side effects may happen from taking the study drug.
Conditions Studied
Interventions
- DRUG Aflibercept 8 mg
Study Locations (20)
Florida
- Advanced Research, LLC - Deerfield Beach
- Florida Retina Institute - Jacksonville - Jacksonville
- Florida Retina Consultants - Lakeland
- Florida Retina Institute - Orlando - Orlando
- Retina Speciality Institute - Pensacola, Florida - Pensacola
- Eye Associates of Pinellas - Pinellas Park
- Retina Vitreous Associates of Florida Saint Petersburg - St. Petersburg
- Retina Vitreous Associates of Florida - Tampa
- Center for Retina and Macular Disease - Winter Haven
California
- Win Retina - Arcadia - Arcadia
- California Retina Consultants - Bakersfield
- Retina Specialists of Beverly Hills - Beverly Hills
- Salehi Retina Institute dba Retina Associates of Southern California - Huntington Beach
- South Coast Retina Center - Long Beach
- California Eye Specialists Medical Group, Inc. - Pasadena
- Retina Consultants of Southern California - Redlands
- Vrmg Inc - Sacramento
Colorado
- Retina Consultants of Southern Colorado - Colorado Springs
- Eye care Center of Northern Colorado doing business as Advanced Vision Research Institute - Longmont
Connecticut
- Retina Group of New England - Waterford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,118 participants |
| Start Date | 2024-07-24 |
| Est. Completion | 2027-01-07 |
| Phase | Phase 3 |
What the registry record for NCT06491914 still lists
NCT06491914 is an interventional study that assigns participants to a tested intervention. Its 1,118 participants enrollment target places it among the larger protocols in the corpus, below the 3,777-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which Aflibercept 8 mg is the first listed.
NCT06491914 names 20 study sites across 4 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06491914 about?
NCT06491914 is a clinical study titled "A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)". This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on participants with nAMD and DME that have been previously treated with anti-vascular endothelial growth factor (anti-VEGF) medications. The aim of the study...
What is the current status of trial NCT06491914?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,118 participants. The study started on 2024-07-24. Estimated completion is 2027-01-07.
What conditions does trial NCT06491914 study?
This clinical trial studies the following conditions: Diabetic Macular Edema, Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT06491914?
The interventions under investigation include: Aflibercept 8 mg (DRUG).
Who is sponsoring clinical trial NCT06491914?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06491914 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06491914's enrollment target sits among peer trials
1,118 4th of 63 higher than 60 of 63 other Diabetic Macular Edema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
RECRUITING · Phase 3
-
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
-
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
ACTIVE NOT RECRUITING · Phase 3
-
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)
ACTIVE NOT RECRUITING · Phase 3
-
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02140255 · 1,120 participants · Phase 1
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
- NCT06618534 · 1,120 participants · Phase 2
Azithromycin for Meningococcal Carriage
- NCT07164131 · 1,120 participants · Phase 4
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams
- NCT05691478 · 1,122 participants · Phase 2
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI